Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
BLENREP is indicated in adults for the treatment of multiple myeloma:1
- In combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and
- In combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide
Missed the live webinar, ‘An MDT approach to multiple myeloma’? View the short clips below for a recap and register here to receive details about future webinars.
WEBINAR: An MDT approach to Multiple Myeloma.
Dr Annabel McMillan, Professor Martin Kaiser and Ewa Kaczmarek discuss an MDT approach to the implementation of Blenrep.
Why is Blenrep a differentiated BCMA-ADC targeted therapy?
A deliverable BCMA targeting therapy in DGH and tertiary settings
Improving outcomes for len refractory multiple myeloma patients in 2L
Case study: Blenrep suitable for a broad range of 2L multiple myeloma patients
Eye-related side effect management
WEBINAR: Blenrep based triplet regimens: Differentiated treatment options for adult patients with multiple myeloma at first relapse
Patient selection and exclusion
Watch Dr Karthik Ramasamy and Dr Rakesh Popat discuss patient selection for BLENREP in their clinical practice
Abbreviations
ADC, antibody-drug conjugate; BCMA, B-cell maturation antigen; Len-refractory, lenalidomide-refractory; MDT, multidisciplinary team; 2L, second-line.
References
- BLENREP. Summary of Product Characteristics. GlaxoSmithKline. 2025.
▼This product is subject to additional monitoring. Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (available on the Apple App Store or Google Play Store). Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or UKSafety@GSK.com.
February 2026 | PM-GB-BLM-WCNT-250041 (V1.0)
